醋酸泼尼松片口服辅助治疗重症心力衰竭的效果
|
摘要
目的探讨醋酸泼尼松片口服辅助治疗重症心力衰竭的临床效果。方法选取2016年1月～2017年12月我院收治的96例重症心力衰竭患者作为研究对象,按照随机数字表法分为两组,每组各48例。对照组予以常规治疗,研究组加以醋酸泼尼松片口服辅助治疗。比较两组患者的临床疗效、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、左心室射血分数(LVEF)、皮质醇(COR)、心房钠尿肽(ANP)、脑钠肽(BNP)水平以及不良反应发生情况。结果研究组的治疗总有效率(93.75%)显著高于对照组(79.17%)(P<0.05);两组患者干预前的LVESD、LVEDD、LVEF、BNP、COR、ANP水平比较,差异无统计学意义(P>0.05);干预后两组的LVESD、LVEDD、BNP、ANP水平均低于干预前,LVEF、COR水平高于干预前(P<0.05);研究组干预后的LVESD、LVEDD、BNP水平低于对照组,LVEF、COR水平高于对照组(P<0.05);研究组的不良反应总发生率(16.67%)与对照组(12.50%)比较,差异无统计学意义(P>0.05)。结论醋酸泼尼松片口服辅助治疗重症心力衰竭的效果确切,可显著改善患者的心功能及神经内分泌因子水平。
Objective To explore the clinical effect of Prednisone Acetate Tablets in oral adjuvant treatment of severe heart failure. Methods A total of 96 patients with severe heart failure admitted to our hospital from January 2016 to December 2017 were selected as the subjects, and divided into two groups according to the random number method,with 48 cases in each group. The control group received routine treatment, and the study group were given oral adjuvant therapy of Prednisone Acetate Tablets. The clinical efficacy, left ventricular end-diastolic diameter(LVEDD), left ventricular end-systolic diameter(LVESD), left ventricular ejection fraction(LVEF), cortisol(COR), atrial natriuretic peptide(ANP), brain sodium Peptide(BNP) levels and adverse events were compared between the two groups. Results The total treatment effective rate of the study group(93.75%) was significantly higher than that of the control group(79.17%)(P<0.05). There were no significant differences in the levels of LVESD, LVEDD, LVEF, BNP, COR and ANP before intervention(P>0.05). The levels of LVESD, LVEDD, BNP and ANP in the two groups after intervention were lower than those before intervention, and LVEF and COR levels were higher than those before intervention(P<0.05).The levels of LVESD, LVEDD and BNP in the study group after intervention were lower than those in the control group, and the levels of LVEF and COR were higher than those in the control group(P<0.05). There was no significant difference in the total incidence of adverse reactions between the study group(16.67%) and the control group(12.50%)(P>0.05). Conclusion Prednisone Acetate Tablets in oral adjuvant treatment of severe heart failure is effective, which can significantly improve the patients′ heart function and neuroendocrine factors levels.
Objective To explore the clinical effect of Prednisone Acetate Tablets in oral adjuvant treatment of severe heart failure. Methods A total of 96 patients with severe heart failure admitted to our hospital from January 2016 to December 2017 were selected as the subjects, and divided into two groups according to the random number method,with 48 cases in each group. The control group received routine treatment, and the study group were given oral adjuvant therapy of Prednisone Acetate Tablets. The clinical efficacy, left ventricular end-diastolic diameter(LVEDD), left ventricular end-systolic diameter(LVESD), left ventricular ejection fraction(LVEF), cortisol(COR), atrial natriuretic peptide(ANP), brain sodium Peptide(BNP) levels and adverse events were compared between the two groups. Results The total treatment effective rate of the study group(93.75%) was significantly higher than that of the control group(79.17%)(P<0.05). There were no significant differences in the levels of LVESD, LVEDD, LVEF, BNP, COR and ANP before intervention(P>0.05). The levels of LVESD, LVEDD, BNP and ANP in the two groups after intervention were lower than those before intervention, and LVEF and COR levels were higher than those before intervention(P<0.05).The levels of LVESD, LVEDD and BNP in the study group after intervention were lower than those in the control group, and the levels of LVEF and COR were higher than those in the control group(P<0.05). There was no significant difference in the total incidence of adverse reactions between the study group(16.67%) and the control group(12.50%)(P>0.05). Conclusion Prednisone Acetate Tablets in oral adjuvant treatment of severe heart failure is effective, which can significantly improve the patients′ heart function and neuroendocrine factors levels.
引文
[1]张静.小剂量甲状腺素联合厄贝沙坦氢氯噻嗪治疗老年重症心力衰竭的观察[J].辽宁医学院学报,2016,37(2):32-34.
[2]李桂仙.甲状腺素联合厄贝沙坦氢氯噻嗪治疗老年重症心力衰竭的临床疗效[J].中国老年学杂志,2016,36(9):2128-2129.
[3]徐利,尹志超.泼尼松片治疗重症心力衰竭的临床疗效及其对神经内分泌因子的影响[J].实用心脑肺血管病杂志,2014,9(10):44-45.
[4]中华医学会心血管病学分会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):3-10.
[5]王中明.厄贝沙坦氢氯噻嗪联合美托洛尔治疗老年重症心力衰竭患者的临床疗效分析[J].中国实用医刊,2016,43(8):90-91.
[6]黄永强.美托洛尔和厄贝沙坦氢氯噻嗪联合治疗老年重症心力衰竭的效果及对BNP水平的影响[J].首都食品与医药,2016,12(4):41-42.
[7]刘鸿宇.小剂量美托洛尔治疗重症心力衰竭的疗效及对患者生活质量的影响[J].实用临床医药杂志,2016,20(13):138-140.
[8]李尚俭,陈新义.糖皮质激素辅助治疗慢性心力衰竭的疗效及其对神经体液因子影响的研究[J].实用医学杂志,2005,21(9):964-966.
[9]谢朝阳.小剂量甲状腺素联合厄贝沙坦氢氯噻嗪治疗老年重症心力衰竭的临床疗效[J].齐齐哈尔医学院学报,2016,37(23):2914-2915.
[10]占长河,林蓉朱.美托洛尔联合厄贝沙坦氢氯噻嗪治疗老年重症心力衰竭的效果研究[J].中外医学研究,2018,16(18):25-27.
[11]裘建萍.酚妥拉明与糖皮质激素联用治疗慢性心力衰竭24例疗效分析[J].工企医刊,2006,19(1):15.
[12]黎辉.厄贝沙坦氢氯噻嗪联合糖皮质激素治疗重症心力衰竭患者临床疗效的研究[J].中国急救医学,2016,36(2):130-133.
[13]黄忠毅.糖皮质激素辅助治疗重症心力衰竭的可行性分析[J].中国当代医药,2018,10(1):135-138.
[14]甄宇治,邓彦东,刘超.糖皮质激素对重症心力衰竭患者神经内分泌因子影响的临床研究[J].中国全科医学,2012,15(1):54-56.
[15]魏新考,李亚昭,崔利锋.糖皮质激素辅助治疗对重症心力衰竭患者心功能及血浆皮质醇、脑钠肽的影响[J].医学综述,2017,23(3):581-584.
[2]李桂仙.甲状腺素联合厄贝沙坦氢氯噻嗪治疗老年重症心力衰竭的临床疗效[J].中国老年学杂志,2016,36(9):2128-2129.
[3]徐利,尹志超.泼尼松片治疗重症心力衰竭的临床疗效及其对神经内分泌因子的影响[J].实用心脑肺血管病杂志,2014,9(10):44-45.
[4]中华医学会心血管病学分会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):3-10.
[5]王中明.厄贝沙坦氢氯噻嗪联合美托洛尔治疗老年重症心力衰竭患者的临床疗效分析[J].中国实用医刊,2016,43(8):90-91.
[6]黄永强.美托洛尔和厄贝沙坦氢氯噻嗪联合治疗老年重症心力衰竭的效果及对BNP水平的影响[J].首都食品与医药,2016,12(4):41-42.
[7]刘鸿宇.小剂量美托洛尔治疗重症心力衰竭的疗效及对患者生活质量的影响[J].实用临床医药杂志,2016,20(13):138-140.
[8]李尚俭,陈新义.糖皮质激素辅助治疗慢性心力衰竭的疗效及其对神经体液因子影响的研究[J].实用医学杂志,2005,21(9):964-966.
[9]谢朝阳.小剂量甲状腺素联合厄贝沙坦氢氯噻嗪治疗老年重症心力衰竭的临床疗效[J].齐齐哈尔医学院学报,2016,37(23):2914-2915.
[10]占长河,林蓉朱.美托洛尔联合厄贝沙坦氢氯噻嗪治疗老年重症心力衰竭的效果研究[J].中外医学研究,2018,16(18):25-27.
[11]裘建萍.酚妥拉明与糖皮质激素联用治疗慢性心力衰竭24例疗效分析[J].工企医刊,2006,19(1):15.
[12]黎辉.厄贝沙坦氢氯噻嗪联合糖皮质激素治疗重症心力衰竭患者临床疗效的研究[J].中国急救医学,2016,36(2):130-133.
[13]黄忠毅.糖皮质激素辅助治疗重症心力衰竭的可行性分析[J].中国当代医药,2018,10(1):135-138.
[14]甄宇治,邓彦东,刘超.糖皮质激素对重症心力衰竭患者神经内分泌因子影响的临床研究[J].中国全科医学,2012,15(1):54-56.
[15]魏新考,李亚昭,崔利锋.糖皮质激素辅助治疗对重症心力衰竭患者心功能及血浆皮质醇、脑钠肽的影响[J].医学综述,2017,23(3):581-584.